Dark

PRN
Invesco Exchange-Traded Fund Trust Invesco Dorsey Wright Industrials Momentum ETF
stock NASDAQ ETF

At Close

Jun 13, 2025 3:59:30 PM EDT

150.35USD-1.254%(-1.91)6,058

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-152.26)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 18, 2022

07:34AM EST Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 CAPTAIN trial. GlobeNewswire Inc

Jan 5, 2022

08:00AM EST Kenneth Knudson Joins Profound Medical as Chief Commercial Officer GlobeNewswire Inc

Nov 4, 2021

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 1, 2021

04:30PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in November. GlobeNewswire Inc

Oct 18, 2021

04:45PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2021 financial results after market close on Thursday, November 4, 2021. GlobeNewswire Inc

Sep 8, 2021

04:30PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announce today that management will participate in two investor conferences in September. GlobeNewswire Inc

Aug 4, 2021

04:05PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021. GlobeNewswire Inc

Jul 15, 2021

04:30PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021. GlobeNewswire Inc

May 25, 2021

04:30PM EDT Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in June. GlobeNewswire Inc

May 19, 2021

04:30PM EDT Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (Profound or the Company) is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the Meeting). A total of 11,810,287 common shares, representing 58.044% of the common shares outstanding, were represented in person and by proxy at the Meeting. GlobeNewswire Inc

May 12, 2021

04:14PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

04:22AM EDT Earnings Scheduled For May 12, 2021 Benzinga

May 6, 2021

07:17AM EDT Profound Medical Says Enters Into U.S. Multi-Center Commercial Agreement With Akumin For TULSA-PRO Benzinga

07:00AM EDT Profound Medical and Akumin Enter into U.S. Multi-Center GlobeNewswire Inc

Apr 21, 2021

04:30PM EDT Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021. GlobeNewswire Inc

Apr 14, 2021

04:30PM EDT Profound Medical to Participate in the 2021 Bloom Burton & Co. GlobeNewswire Inc

Mar 3, 2021

07:00AM EST Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors. GlobeNewswire Inc

Mar 2, 2021

04:02PM EST Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2020. GlobeNewswire Inc

Feb 11, 2021

04:30PM EST Profound Medical to Participate in the BTIG Virtual MedTech, GlobeNewswire Inc

Feb 9, 2021

04:30PM EST Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2020 financial results after market close on Tuesday, March 2, 2021. GlobeNewswire Inc

Jan 5, 2021

04:30PM EST Profound Medical Announces Preliminary Unaudited Fourth Quarter GlobeNewswire Inc

Dec 21, 2020

07:30AM EST Profound Medical Signs Agreement with GE Healthcare to Expand GlobeNewswire Inc

Nov 30, 2020

08:06AM EST Profound Medical Receives FDA HDE Approval For Sonalleve Benzinga

08:00AM EST Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) announced today that Sonalleve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE) for the treatment of osteoid osteoma. GlobeNewswire Inc

07:45AM EST Profound Medical Announces Changes to its Board of Directors GlobeNewswire Inc

Oct 15, 2020

04:30PM EDT Profound Medical to Release Third Quarter 2020 Financial Results GlobeNewswire Inc

Sep 9, 2020

04:30PM EDT Profound Medical to Present at the Cantor Virtual Global GlobeNewswire Inc

Aug 10, 2020

08:00AM EDT Profound Medical Present at the Canaccord Genuity 40th Annual GlobeNewswire Inc

Jul 22, 2020

08:00AM EDT Profound Medical to Release Second Quarter 2020 Financial Results GlobeNewswire Inc

Jul 21, 2020

12:35PM EDT Profound Medical Announces Closing of Offering GlobeNewswire Inc

Jul 15, 2020

08:59PM EDT Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (Profound or the Company) is pleased to announce the pricing of an underwritten public offering (the Offering) of 2,758,621 common shares of the Company (the Common Shares), at a price of US$14.50 per Common Share (the Offering Price). GlobeNewswire Inc

04:01PM EDT Profound Medical Announces Proposed Offering of Common Shares GlobeNewswire Inc